BCL2 expression and GCMN cell survival
BCL2 expression contributes to the prolonged survival of both P16+ senescent and Ki67+ proliferative giant congenital melanocytic nevus (GCMN) cells. Clinically, GCMN lesions maintain consistent dimensions…
Anti-BCL2 therapy eliminates giant congenital melanocytic nevus by senolytic and immune induction
